XML 19 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814
Licensing, Acquisitions and Other Arrangements (Details 2) - USD ($)
$ in Millions
3 Months Ended 4 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2015
Sep. 30, 2014
May. 26, 2015
Dec. 31, 2014
Assets acquired and liabilities assumed              
Goodwill $ 13,243   $ 13,243 $ 13,243     $ 5,862
Net Revenues 5,944 $ 5,019   16,459 $ 14,508    
Operating loss 1,885 $ 960   5,424 $ 3,826    
Pharmacyclics Inc              
Assets acquired and liabilities assumed              
Cash and equivalents           $ 877  
Short-term investments           11  
Accounts and other receivables           106  
Inventories           492  
Other assets           212  
Accounts payable and accrued liabilities           (381)  
Deferred income taxes           (6,453)  
Other long-term liabilities           (254)  
Total identifiable net assets           13,160  
Goodwill           7,610  
Total assets acquired and liabilities assumed           20,770  
Fair market value step-up adjustment to inventories $ 445   445 $ 445      
Amortized period of inventory       18 months      
Finite intangible assets weighted-average estimated useful life       13 years      
Net Revenues     431        
Operating loss     (422)        
Acquisition-related compensation expense     294        
Acquisition-related inventory step up and amortization of intangible assets     144        
Acquisition-related transaction and integration costs     96        
Pharmacyclics Inc | IPR&D              
Assets acquired and liabilities assumed              
Intangible assets           7,180  
Pharmacyclics Inc | Developed product rights              
Assets acquired and liabilities assumed              
Intangible assets           4,590  
Pharmacyclics Inc | License agreements              
Assets acquired and liabilities assumed              
Intangible assets           $ 6,780  
Pharmacyclics Inc | Selling, general and administrative expense              
Assets acquired and liabilities assumed              
Acquisition-related costs     279        
Pharmacyclics Inc | R&D              
Assets acquired and liabilities assumed              
Acquisition-related costs     111        
Pharmacyclics Inc | Cost of products sold              
Assets acquired and liabilities assumed              
Acquisition-related costs     $ 144